Machina Capital S.A.S. Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Machina Capital S.A.S. acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 18,077 shares of the medical device company's stock, valued at approximately $1,234,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jennison Associates LLC lifted its stake in DexCom by 37.7% in the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock valued at $718,632,000 after acquiring an additional 2,879,489 shares during the last quarter. Geode Capital Management LLC boosted its position in DexCom by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock worth $775,256,000 after purchasing an additional 56,094 shares during the period. Norges Bank acquired a new position in DexCom during the fourth quarter valued at approximately $385,367,000. Northern Trust Corp lifted its stake in shares of DexCom by 22.2% in the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock worth $322,454,000 after buying an additional 753,857 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in DexCom by 171.0% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock valued at $218,175,000 after buying an additional 2,015,971 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 10,000 shares of DexCom stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the transaction, the executive vice president directly owned 95,602 shares of the company's stock, valued at $8,057,336.56. This trade represents a 9.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 6,184 shares of the company's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the sale, the executive vice president owned 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,190 shares of company stock worth $2,281,732 in the last ninety days. 0.32% of the stock is currently owned by corporate insiders.

DexCom Trading Up 2.6%

Shares of NASDAQ:DXCM traded up $2.25 during trading on Friday, hitting $88.99. 3,072,147 shares of the company's stock were exchanged, compared to its average volume of 2,733,721. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55. The firm has a market cap of $34.89 billion, a P/E ratio of 66.41, a PEG ratio of 1.85 and a beta of 1.44. The firm has a 50-day moving average price of $84.58 and a two-hundred day moving average price of $80.41. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the business posted $0.32 earnings per share. DexCom's revenue was up 12.5% compared to the same quarter last year. Equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on DXCM shares. Wall Street Zen raised DexCom from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Citigroup reiterated a "buy" rating and set a $102.00 target price (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Piper Sandler reduced their target price on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Morgan Stanley raised their price objective on DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Finally, Truist Financial initiated coverage on shares of DexCom in a report on Monday, June 16th. They issued a "buy" rating and a $102.00 price target on the stock. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $99.60.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.